{"id":785676,"date":"2023-09-22T08:18:09","date_gmt":"2023-09-22T12:18:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\/"},"modified":"2023-09-22T08:18:09","modified_gmt":"2023-09-22T12:18:09","slug":"rhythm-pharmaceuticals-presents-new-data-at-espe-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\/","title":{"rendered":"Rhythm Pharmaceuticals Presents New Data at ESPE 2023"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, Sept.  22, 2023  (GLOBE NEWSWIRE) &#8212; Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced four oral presentations at the 61<sup>st<\/sup> Annual European Society for Paediatric Endocrinology (ESPE) Meeting being held September 21-23, 2023 in The Hague, Netherlands.<\/p>\n<p>\u201cWe are excited to deliver multiple presentations at ESPE 2023 including statistics that deepen the understanding of the genetics of obesity from our Rare Obesity Advanced Diagnosis\u2122 (ROAD) testing program as we learn more about the importance of genetics in patients with early-onset, severe obesity,\u201d said David Meeker, M.D., Chair, President and Chief Executive Officer of Rhythm.<\/p>\n<p>\n        <strong>Impact of Setmelanotide on Metabolic Syndrome Risk<\/strong><br \/>\n        <br \/>Andrea Haqq, M.D., Division of Pediatric Endocrinology, University of Alberta in Canada, and Jes\u00fas Argente M.D., Ph.D., Department of Pediatrics and Pediatric Endocrinology, Universidad Aut\u00f3noma de Madrid in Spain, delivered an oral presentation on the effects of setmelanotide on the metabolic syndrome severity score based on body mass index (MetS-Z-BMI) score in pediatric patients with Bardet-Biedl syndrome (BBS).<\/p>\n<p>In an oral presentation titled, \u201cImpact of Setmelanotide on Metabolic Syndrome Risk in Pediatric Patients with POMC and LEPR Deficiency,\u201d researchers led by Martin Wabitsch, M.D., Ph.D., Department of Pediatrics and Adolescent Medicine, University of Ulm in Germany, presented new findings regarding setmelanotide treatment in pediatric patients with pro-opiomelanocortin (POMC) or leptin receptor (LEPR) deficiency.<\/p>\n<p>\n        <strong>Analyses from ROAD genetic testing program<\/strong><br \/>\n        <br \/>In an oral presentation titled, \u201cFrequency of MC4R Pathway Variants in a European Cohort of Individuals with Early-Onset Severe Obesity,\u201d researchers led by Anthony Goldstone, M.D., Ph.D., Department of Brain Sciences, Imperial College London, assessed a large European-based cohort of individuals with early-onset severe obesity, finding that 20.4% of individuals sequenced carried a variant in one or more of 11 specific MC4R pathway-related genes, including 5.0% of individuals with variants classified as pathogenic, likely pathogenic or suspected pathogenic.<\/p>\n<p>\u201cFrequency of Obesity-Related Gene Variants in a European Population with Early-Onset, Severe Obesity,\u201d as presented orally by Jes\u00fas Argente M.D., Ph.D., Department of Pediatrics and Pediatric Endocrinology, Universidad Aut\u00f3noma de Madrid in Spain, shows that among individuals with early-onset, severe obesity, approximately 31.4% carried variants believed to be associated with obesity.<\/p>\n<p>In addition, Rhythm is hosting a satellite symposium at ESPE 2023, titled, \u201cHyperphagia and early-onset, severe obesity: The role of precision medicine in the treatment of leptin melanocortin-4 receptor (MC4R) pathway diseases.\u201d<\/p>\n<p>\n        <strong>About\u00a0Rhythm Pharmaceuticals<\/strong> \u00a0<br \/>Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. Rhythm\u2019s product, IMCIVREE (setmelanotide) is approved by the\u00a0U.S. Food and Drug Administration\u00a0(FDA) and authorized by the European Medicines Agency\u00a0(and the UK\u2019s\u00a0Medicines &amp; Healthcare Products Regulatory Agency\u00a0(MHRA) for use in accordance with product labeling. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. Rhythm\u2019s headquarters is in\u00a0Boston, MA.\u00a0\u00a0<\/p>\n<p>\n        <strong>Forward-looking Statements<\/strong>\u00a0\u00a0<br \/>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the potential, safety, efficacy, and regulatory and clinical progress of setmelanotide, the potential benefits of setmelanotide for patients with cardiovascular diseases and type 2 diabetes mellitus, as well as severe obesity due to certain genetic deficiencies, expectations regarding the prevalence of patients living with MC4R pathway-related gene variants, and our participation in upcoming events and presentations.\u00a0 Statements using words such as \u201cexpect\u201d, \u201canticipate\u201d, \u201cbelieve\u201d, \u201cmay\u201d, \u201cwill\u201d and similar terms are also forward-looking statements. Such statements are subject to numerous risks and uncertainties, including, but not limited to, risks relating to our liquidity and expenses, our ability to enroll patients in clinical trials, the design and outcome of clinical trials, the ability to achieve necessary regulatory approvals, risks associated with data analysis and reporting, failure to identify and develop additional product candidates, unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, risks associated with the laws and regulations governing our international operations and the costs of any related compliance programs, our ability to obtain or maintain orphan drug designations for setmelanotide or to obtain or maintain exclusivity in any use, the impact of competition, risks relating to product liability lawsuits, inability to maintain our collaborations, or the failure of these collaborations, our reliance on third parties, risks relating to intellectual property, our ability to hire and retain necessary personnel, the impact of the COVID-19 pandemic and general economic conditions on our business and operations, including our preclinical studies, clinical trials and commercialization prospects, and the other important factors discussed under the caption \u201cRisk Factors\u201d in our Quarterly Report on Form 10-Q for the three months ended June 30, 2023\u00a0and our other filings with the\u00a0Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.\u00a0\u00a0<\/p>\n<p>\n        <strong>Corporate Contact:<\/strong><br \/>\n        <br \/>David Connolly<br \/>Executive Director, Investor Relations and Corporate Communications<br \/>Rhythm Pharmaceuticals, Inc.<br \/>857-264-4280<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_b6onwPxI8kQjqeAw6tkSfqUuedBEzaoYjd019E1k5gAGOfuCNrWfola01dmjxDX8IDWNJD3TJI-qj1rNj0iQMksUUe0nDBQMpjnKoJCdDVAgCRNFzz8S5G3XxeyZpUZ0JFfm-_lX5ykLGBWqzbwWE_XNsrDuOejA7KFk-ItVs3fXAABWJgEtONjfAcbY_CH4EstYdjWQjgUXdaZ4ztykRSBpl-BUhLOMwqJty8pL49htBtszeT7yX2-unTewD2Q1ZOJ1ocZLEGxf52ytxLSlA==\" rel=\"nofollow noopener\" target=\"_blank\"><u>dconnolly@rhythmtx.com<\/u><\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Adam Daley<br \/>Berry &amp; Company Public Relations<br \/>212-253-8881<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rFplpY3KaKS8JVdy_r58ILieOhTR1PwtxMEd9qff1j95akWQHyrBqqwkSM-LvFrlRCRa8i3krL543SIS7aJQcsncVcrUx54ijfhI8de_Ii5i52P5gghR8bjZHrYhFAdktIdVYr2dWghVJ6h0c4REbsMEdsOuP03FuIqA7jtaYdY8lPjYfbuF168-y9ngYDb8GODai3QN2nWmfcO3jpIorm9t-CWwX4nnnv8WuqeTUUCuNg7-hBOZ6nWC-oMgyA_Or9r0wIps1SnvhRKkC9YP8A==\" rel=\"nofollow noopener\" target=\"_blank\"><u>adaley@berrypr.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNjUwMiM1ODI2NzUyIzIwMTEyMDQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NDNkMjg2NDMtNTY4Yy00NGNmLTgyMzYtNDU0NWEwYzU2ZjQ4LTEwMjI3Nzc=\/tiny\/Rhythm-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) &#8212; Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced four oral presentations at the 61st Annual European Society for Paediatric Endocrinology (ESPE) Meeting being held September 21-23, 2023 in The Hague, Netherlands. \u201cWe are excited to deliver multiple presentations at ESPE 2023 including statistics that deepen the understanding of the genetics of obesity from our Rare Obesity Advanced Diagnosis\u2122 (ROAD) testing program as we learn more about the importance of genetics in patients with early-onset, severe obesity,\u201d said David Meeker, M.D., Chair, President and Chief Executive Officer &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Rhythm Pharmaceuticals Presents New Data at ESPE 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-785676","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rhythm Pharmaceuticals Presents New Data at ESPE 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rhythm Pharmaceuticals Presents New Data at ESPE 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) &#8212; Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced four oral presentations at the 61st Annual European Society for Paediatric Endocrinology (ESPE) Meeting being held September 21-23, 2023 in The Hague, Netherlands. \u201cWe are excited to deliver multiple presentations at ESPE 2023 including statistics that deepen the understanding of the genetics of obesity from our Rare Obesity Advanced Diagnosis\u2122 (ROAD) testing program as we learn more about the importance of genetics in patients with early-onset, severe obesity,\u201d said David Meeker, M.D., Chair, President and Chief Executive Officer &hellip; Continue reading &quot;Rhythm Pharmaceuticals Presents New Data at ESPE 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-22T12:18:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNjUwMiM1ODI2NzUyIzIwMTEyMDQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Rhythm Pharmaceuticals Presents New Data at ESPE 2023\",\"datePublished\":\"2023-09-22T12:18:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\\\/\"},\"wordCount\":939,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyNjUwMiM1ODI2NzUyIzIwMTEyMDQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\\\/\",\"name\":\"Rhythm Pharmaceuticals Presents New Data at ESPE 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyNjUwMiM1ODI2NzUyIzIwMTEyMDQ=\",\"datePublished\":\"2023-09-22T12:18:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyNjUwMiM1ODI2NzUyIzIwMTEyMDQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyNjUwMiM1ODI2NzUyIzIwMTEyMDQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rhythm Pharmaceuticals Presents New Data at ESPE 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rhythm Pharmaceuticals Presents New Data at ESPE 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\/","og_locale":"en_US","og_type":"article","og_title":"Rhythm Pharmaceuticals Presents New Data at ESPE 2023 - Market Newsdesk","og_description":"BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) &#8212; Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced four oral presentations at the 61st Annual European Society for Paediatric Endocrinology (ESPE) Meeting being held September 21-23, 2023 in The Hague, Netherlands. \u201cWe are excited to deliver multiple presentations at ESPE 2023 including statistics that deepen the understanding of the genetics of obesity from our Rare Obesity Advanced Diagnosis\u2122 (ROAD) testing program as we learn more about the importance of genetics in patients with early-onset, severe obesity,\u201d said David Meeker, M.D., Chair, President and Chief Executive Officer &hellip; Continue reading \"Rhythm Pharmaceuticals Presents New Data at ESPE 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-22T12:18:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNjUwMiM1ODI2NzUyIzIwMTEyMDQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Rhythm Pharmaceuticals Presents New Data at ESPE 2023","datePublished":"2023-09-22T12:18:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\/"},"wordCount":939,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNjUwMiM1ODI2NzUyIzIwMTEyMDQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\/","name":"Rhythm Pharmaceuticals Presents New Data at ESPE 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNjUwMiM1ODI2NzUyIzIwMTEyMDQ=","datePublished":"2023-09-22T12:18:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNjUwMiM1ODI2NzUyIzIwMTEyMDQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNjUwMiM1ODI2NzUyIzIwMTEyMDQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-presents-new-data-at-espe-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Rhythm Pharmaceuticals Presents New Data at ESPE 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/785676","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=785676"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/785676\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=785676"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=785676"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=785676"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}